Companies · Pharmaceuticals

Aquinox Pharmaceuticals (Usa) Inc

RICHMOND · Pharmaceuticals

Diligence memoA one-page analyst read on Aquinox Pharmaceuticals (Usa) Inc — recommendation, valuation, rhythm, risks.
$30.6M
Total raised · real
5
Rounds
4.0×
Latest step-up
Top 27%
Sector rank · raised
Series A
Latest stage · inferred · Tue Mar 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time)

Aquinox Pharmaceuticals (Usa) Inc looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.21× the median modeled value of Series A Pharmaceuticals companies in 2013–2015 (64 peers) — value vs value, same stage and era.
Dormant
  • Last raise 13.3 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Aquinox Pharmaceuticals (Usa) Inc is one of 1613 Pharmaceuticals companies tracked from RICHMOND. By capital raised it ranks in the upper tier (ahead of 74% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2010-03-31 Raised $4.8M (real) Modeled valuation $150M (est)$4.8M$150MSeries A2010Series A · 2010-06-14 Raised $3.5M (real) Modeled valuation $109M (est)$3.5M$109MSeries A2010Series A · 2011-01-31 Raised $4.7M (real) Modeled valuation $146M (est)$4.7M$146MSeries A2011Series A · 2011-09-21 Raised $3.5M (real) Modeled valuation $110M (est)$3.5M$110MSeries A2011Series A · 2013-03-19 Raised $14M (real) Modeled valuation $434M (est)$14M$434MSeries A2013+$3.5M+$4.7M+$3.5M+$14MCumulative $31M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$4.8M · 2010
Series A extension$3.5M · 2010
Series A extension$4.7M · 2011
Series A extension$3.5M · 2011
Series A extension$14.0M · 2013

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$433.6M
Base estimate est.
$16.0M
Conservative case
$2.4B
Upside case
$63.6M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Series A · modeled $149.5M · 2010-03-312010Series A · modeled $109.4M · 2010-06-14Series A · modeled $146.3M · 2011-01-31Series A · modeled $109.5M · 2011-09-21Series A · modeled $433.6M · 2013-03-192013
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
46%
Survival probability
25% low · 63% high
1.57×/yr
Annual markup
1.97×/yr upside case
6.0 yr
Elapsed time used
13.3 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
9 mo
Avg between rounds
$10.3M/yr
Capital velocity
16.3 yr
On record since
2010
First round
5
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 3.8× above median
This company$30.6M
Sector median$8.1M
Latest round — vs other Series A rounds in sector (real $, this stage) 2.7× above median
This company$14.0M
Sector median$5.2M
Modeled value — vs sector median (estimate, all stages) 5.7× above median
This company$433.6M
Sector median$76.1M

Raised more than 74% of sector peers (real $). Modeled value above 79% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #1 of 64.

This companyCohort peer
$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Neurovia, Inc. · Series A Raised $13.9M · modeled $432.1M (est)Romark Global Pharma, LLC · Series A Raised $13.8M · modeled $428.5M (est)Access Pharmaceuticals Inc · Series A Raised $39.2M · modeled $423.2M (est)Minnesota Medical Solutions LLC · Series A Raised $16.6M · modeled $402.6M (est)OncoQuest Inc. · Series A Raised $13.0M · modeled $402.6M (est)Immune Pharmaceuticals Inc · Series A Raised $11.7M · modeled $363.0M (est)Great Lakes Pharmaceuticals, Inc. · Series A Raised $11.2M · modeled $347.5M (est)Rhythm Holding Company, LLC · Series A Raised $11.0M · modeled $340.7M (est)Pharmatrophix Inc · Series A Raised $16.8M · modeled $319.0M (est)Vesuvius Pharmaceuticals, Inc. · Series A Raised $10.2M · modeled $316.7M (est)CoStim Pharmaceuticals Inc. · Series A Raised $10.0M · modeled $309.9M (est)Aquinox Pharmaceuticals (Usa) Inc (this company) Raised $30.6M · modeled $433.6M (est)Aquinox Pharmaceuticals (Usa) Inc
CompanyStageRaised · realValue · estvs peer med.
Aquinox Pharmaceuticals (Usa) Inc this companySeries A$30.6M$433.6M2.21×
Neurovia, Inc.Series A$13.9M$432.1M2.20×
Romark Global Pharma, LLCSeries A$13.8M$428.5M2.18×
Access Pharmaceuticals IncSeries A$39.2M$423.2M2.16×
Minnesota Medical Solutions LLCSeries A$16.6M$402.6M2.05×
OncoQuest Inc.Series A$13.0M$402.6M2.05×
Immune Pharmaceuticals IncSeries A$11.7M$363.0M1.85×
Great Lakes Pharmaceuticals, Inc.Series A$11.2M$347.5M1.77×
Rhythm Holding Company, LLCSeries A$11.0M$340.7M1.74×
Pharmatrophix IncSeries A$16.8M$319.0M1.62×
Vesuvius Pharmaceuticals, Inc.Series A$10.2M$316.7M1.61×
CoStim Pharmaceuticals Inc.Series A$10.0M$309.9M1.58×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$4.8M2010-03-31$21.9M$149.5M90%
Series A$3.5M2010-06-14$16.1M$109.4M90%
Series A$4.7M2011-01-31$21.5M$146.3M90%
Series A$3.5M2011-09-21$16.1M$109.5M90%
Series A$14.0M2013-03-19$63.6M$433.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$4.8M2010-03-31
    • First recorded raise — entered as Series A.
  2. Series A$3.5M2010-06-14
    • Came back fast: 2 mo vs the ~13 mo sector norm.
    • Round 1.4× smaller than the prior — bridge or down round.
  3. Series A$4.7M2011-01-31
    • Came back fast: 8 mo vs the ~13 mo sector norm.
    • Round 1.3× larger than the prior — scaling up.
  4. Series A$3.5M2011-09-21
    • Came back fast: 8 mo vs the ~13 mo sector norm.
    • Round 1.3× smaller than the prior — bridge or down round.
  5. Series A$14.0M2013-03-19
    • Raised 18 mo later, in step with the ~13 mo sector norm.
    • Round 4.0× larger than the prior — scaling up.
Intelligence
2013 ~Q4
Modeled next raise · ~9mo cadence
$42.0M
Modeled next size est.range $27.3M$67.2M
4.0×
Last step-up
$10.3M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Asish Xavier17 other2013-03
Elaine Jones5 other2013-03
Kenneth Galbraith5 other2013-03
Daniel Levitt1 other2013-03
David Main1 other2013-03
ELAINE J. JONES1 other2011-09
Asish H. Xavier2010-03
Asish J. Xavier2011-09
Daniel H. Levitt2010-03
Daniel J. Levitt2011-09
David J. Main2010-03
Elaine H. Jones2011-01
Frank H. Holler2011-01
Frank J. Holler2011-09
Kamran Alam2013-03
Kamran J. Alam2011-09
Kenneth H. Galbraith2010-03
Kenneth J. Galbraith2011-09
Kevin H. Leslie2010-03
Stephen H. Majlath2010-03
Registry & provenance

Aquinox Pharmaceuticals (Usa) Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1404644
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Receptos, Inc. (f.k.a. Receptor Pharmaceuticals Inc.)PharmaceuticalsSeries A$30.5M$334.7Msame sector · same stage
Zosano Pharma CorpPharmaceuticalsSeries A$29.7M$233.4Msame sector · same stage
Zikani Therapeutics, Inc.PharmaceuticalsSeries A$31.7M$232.3Msame sector · same stage
Harrow Health, Inc.PharmaceuticalsSeries A$29.2M$226.5Msame sector · same stage
Processa Pharmaceuticals, Inc.PharmaceuticalsSeries A$29.0M$239.2Msame sector · same stage
Aytu Bioscience, IncPharmaceuticalsSeries A$28.8M$309.7Msame sector · same stage
Blue Rabbit Ventures, Inc.PharmaceuticalsSeries A$28.2M$219.6Msame sector · same stage
Tetralogic Pharmaceuticals CorpPharmaceuticalsSeries A$27.9M$154.9Msame sector · same stage
Frequently asked
How much funding has Aquinox Pharmaceuticals (Usa) Inc raised?
Aquinox Pharmaceuticals (Usa) Inc has raised approximately $30.6M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is Aquinox Pharmaceuticals (Usa) Inc's estimated valuation?
Provath's modeled valuation for Aquinox Pharmaceuticals (Usa) Inc is approximately $433.6M (modeled range $16.0M–$2.4B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Aquinox Pharmaceuticals (Usa) Inc at?
Aquinox Pharmaceuticals (Usa) Inc's latest modeled financing stage is Series A. Its most recent recorded round closed around Tue Mar 19.
What does Aquinox Pharmaceuticals (Usa) Inc do and where is it based?
Aquinox Pharmaceuticals (Usa) Inc operates in the Pharmaceuticals sector, based in RICHMOND.
Explore related

See where Aquinox Pharmaceuticals (Usa) Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Aquinox Pharmaceuticals (Usa) Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.